Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian P Gee

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Scientific Reports|April 28, 2017
Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple CentersShutong Liu, Luis F de Castro, Ping Jin, et al.
Blood Advances|July 12, 2019
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipientsAllistair A Abraham, Tami D John, Michael D Keller, et al.
Transfusion|February 11, 2012
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) studySara Richman, Adrian P Gee, David H McKenna, et al.
Blood|May 16, 2015
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantationXiaoou Zhou, Gianpietro Dotti, Robert A Krance, et al.
Cytotherapy|August 21, 2012
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applicationsNatalia Lapteva, April G Durett, Jiali Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteinsCatherine M Bollard, Stephen Gottschalk, Vicky Torrano, et al.
Journal for Immunotherapy of Cancer|March 4, 2015
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational applicationJiali Sun, Leslie E Huye, Natalia Lapteva, et al.
The New England Journal of Medicine|November 4, 2011
Inducible apoptosis as a safety switch for adoptive cell therapyAntonio Di Stasi, Siok-Keen Tey, Gianpietro Dotti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 13, 2018
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's LymphomasCarlos A Ramos, Rayne Rouce, Catherine S Robertson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2018
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin LymphomaCatherine M Bollard, Tamara Tripic, Conrad Russell Cruz, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Scientific Reports|April 28, 2017
Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple CentersShutong Liu, Luis F de Castro, Ping Jin, et al.
Blood Advances|July 12, 2019
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipientsAllistair A Abraham, Tami D John, Michael D Keller, et al.
Transfusion|February 11, 2012
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) studySara Richman, Adrian P Gee, David H McKenna, et al.
Blood|May 16, 2015
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantationXiaoou Zhou, Gianpietro Dotti, Robert A Krance, et al.
Cytotherapy|August 21, 2012
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applicationsNatalia Lapteva, April G Durett, Jiali Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteinsCatherine M Bollard, Stephen Gottschalk, Vicky Torrano, et al.
Journal for Immunotherapy of Cancer|March 4, 2015
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational applicationJiali Sun, Leslie E Huye, Natalia Lapteva, et al.
The New England Journal of Medicine|November 4, 2011
Inducible apoptosis as a safety switch for adoptive cell therapyAntonio Di Stasi, Siok-Keen Tey, Gianpietro Dotti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 13, 2018
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's LymphomasCarlos A Ramos, Rayne Rouce, Catherine S Robertson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2018
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin LymphomaCatherine M Bollard, Tamara Tripic, Conrad Russell Cruz, et al.
Pageof 9